<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recent studies in several <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> models indicated that treatment with angiogenic inhibitors may trigger induction of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> to other organs </plain></SENT>
<SENT sid="1" pm="."><plain>Here we investigated modes of resistance and invasion in several <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines including 4T1 (breast), H460 (lung) and Colo205 (colorectal) using <z:chebi fb="0" ids="38940">sunitinib</z:chebi> at doses comparable to clinically utilized regimen </plain></SENT>
<SENT sid="2" pm="."><plain>In comparison with vehicle-treated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, <z:chebi fb="0" ids="38940">sunitinib</z:chebi> increased <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">metastasis to lung</z:e> in 4T1 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and to peritoneal lymph node in Colo205 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>However, the same treatment did not induce invasiveness in H460 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, further suggesting that accelerating <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> during treatment with angiogenic inhibitors is <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell-type dependent </plain></SENT>
<SENT sid="4" pm="."><plain>Interestingly, Crizotinib (a dual inhibitor of c-Met and ALK pathways) as single agent or in combination with <z:chebi fb="0" ids="38940">sunitinib</z:chebi> reduced <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> in <z:hpo ids='HP_0000001'>all</z:hpo> models tested suggesting a role for c-Met/HGF pathway in intrinsic- or <z:chebi fb="0" ids="38940">sunitinib</z:chebi>-induced-<z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, ELISA data showed that while c-Met is highly enriched in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells, HGF is secreted mainly by the stroma (mouse HGF) suggesting a paracrine fashion for c-Met pathway activation in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>In conclusion, our findings indicate that <z:chebi fb="0" ids="38940">sunitinib</z:chebi>-induced <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> is <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell-type dependent and further supports a rationale for combination of anti-angiogenics and c-Met inhibition in the clinic </plain></SENT>
</text></document>